Emergent Biosolutions (EBS) Misses Q2 EPS by 2c; Mixed Guidance
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.76 --0%
EPS Growth %: -138.7%
Financial Fact:
Provision for (benefit from) income taxes: 13.17M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -138.7%
Financial Fact:
Provision for (benefit from) income taxes: 13.17M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Emergent Biosolutions (NYSE: EBS) reported Q2 EPS of $0.21, $0.02 worse than the analyst estimate of $0.23. Revenue for the quarter came in at $70.4 million versus the consensus estimate of $76.2 million.
Emergent Biosolutions sees FY2012 revenue of $60-$70 million, versus the consensus of $78.32 million.
Emergent Biosolutions sees FY2012 revenue of $280-$300 million, versus the consensus of $292.99 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Emergent Biosolutions sees FY2012 revenue of $60-$70 million, versus the consensus of $78.32 million.
Emergent Biosolutions sees FY2012 revenue of $280-$300 million, versus the consensus of $292.99 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
- Morgan Stanley refreshes Strait of Hormuz reopening analysis
- Goldman Sachs Downgrades Bank Mandiri (BMRI:IJ) (PPERF) to Sell, 'Liquidity and capital tightness'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
